金刚烷胺在帕金森病及其他运动障碍中的应用
本文综述金刚烷胺治疗帕金森病及其他运动障碍的证据。金刚烷胺兼具多巴胺能和谷氨酸能作用,随机对照试验证实其可改善帕金森病患者的左旋多巴诱导的运动障碍,并可能减少运动波动;其他适应症证据不足。
要点
- 金刚烷胺对帕金森病症状和左旋多巴诱导的运动障碍均有疗效。
- 近5年随机对照试验证实其治疗左旋多巴诱导运动障碍有效。
- 治疗药物性帕金森综合征等适应症缺乏强证据支持。
核心结论
- 金刚烷胺对帕金森病症状及左旋多巴诱导的运动障碍有效,并可能减少运动波动。
研究设计与样本
- 综述总结了逾50年的临床使用经验及近5年随机对照试验证据。
主要发现
- 金刚烷胺兼具多巴胺能和谷氨酸能特性,另有抗胆碱能和5-羟色胺能作用。
- 随机对照试验证实金刚烷胺可治疗帕金森病患者的左旋多巴诱导的运动障碍。
- 临床研究支持金刚烷胺可能减少运动波动。
- 治疗药物性帕金森综合征、非典型帕金森综合征、亨廷顿病或迟发性运动障碍缺乏强证据。
临床怎么用
- 金刚烷胺仍被神经科医生常用于治疗帕金森病。
- 可考虑用于改善帕金森病患者的左旋多巴诱导的运动障碍和运动波动。
局限性
- 治疗药物性帕金森综合征、非典型帕金森综合征、亨廷顿病或迟发性运动障碍缺乏强证据支持。
- 未来需研究金刚烷胺在早期帕金森病及其他运动障碍中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy of amantadine in the symptomatic treatment of patients with Parkinson's disease, discovered serendipitously more than 50 years ago, has stood the test of time and the drug is still commonly used by neurologists today. Its pharmacological actions are unique in combining dopaminergic and glutamatergic properties, which account for its dual effect on parkinsonian signs and symptoms and levodopa-induced dyskinesias. Furthermore, amantadine has additional and less well-defined pharmacological effects, including on anticholinergic and serotonergic activity. Evidence from randomised controlled trials over the past 5 years has confirmed the efficacy of amantadine to treat levodopa-induced dyskinesias in patients with Parkinson's disease, and clinical studies have also provided support for its potential to reduce motor fluctuations. Other uses of amantadine, such as in the treatment of drug-induced parkinsonism, atypical parkinsonism, Huntington's disease, or tardive dyskinesia, lack a strong evidence base. Future trials should examine its role in the management of motor and non-motor symptoms in patients with early Parkinson's disease and those with other movement disorders.
引用
- Rascol O, Fabbri M, Poewe W, et al. Amantadine in the treatment of Parkinson's disease and other movement disorders. Lancet Neurol. 2021. PMID: 34678171. doi:10.1016/S1474-4422(21)00249-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。